CONMED Corporation
CNMDMedical Devices
$44.29−3.13%As of Oct 30vs prior close
- Market cap
- $1.3B
- P/E (TTM)
- 20.4×
- P/E (FY1)
- 9.8×
- Implied growth
- 4.3%
- From 52W high
- −14.60%
- EPS (LTM)
- $2.16
- Revenue (LTM)
- $1.4B
- Net margin
- 4.78%
- Dividend yield
- –
Nomior Score
61
Discounted QualitySpeculativeTop 25% of the scored universe
Growth36
Quality69
Value86
Momentum48
Resilience46
Growth
+6.75%revenue a year over 9 fiscal years
YE16 $763.5MLTM $1.4B
Connections
Revenue to profitQ3 YE26
6% of revenue became net profit.
Latest resultsThird Quarter 2026
- Revenue
- $335.6 million
- Diluted EPS
- $0.66
- Adjusted EPS
- $1.04
Reported sales fell slightly in the quarter, with domestic sales declining while international sales grew, and excluding the exited gastroenterology product offerings organic constant currency sales grew. GAAP diluted earnings per share rose sharply from a low prior-year base, while adjusted diluted earnings per share declined modestly. The company updated its full-year guidance, with the adjusted EPS range moving slightly higher.
Who owns it
2funds